Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649621 | 1.00 | TRPA1 (0.42) | TRPA1TNKSPARP1TNKS2AAK1 | |
| SCHEMBL5649627 | 1.00 | TRPA1 (0.42) | TRPA1TNKSPARP1TNKS2AAK1 | |
| SCHEMBL4075226 | 0.77 | AAK1 (0.51) | TRPA1AAK1ADORA3TP53KDM4E | |
| SCHEMBL24807720 | 0.75 | LMNA (0.50) | LMNAPOLBSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL21729493 | 0.75 | AAK1 (0.42) | TRPA1AAK1LMNASMN1; SMN2KDM4E | |
| SCHEMBL28457041 | 0.75 | AAK1 (0.42) | TRPA1AAK1LMNASMN1; SMN2KDM4E | |
| SCHEMBL28446403 | 0.75 | ABCB1 (0.37) | AAK1LMNAMEN1KMT2AABCB1 | |
| SCHEMBL4154097 | 0.75 | AAK1 (0.46) | TRPA1AAK1LMNASMN1; SMN2TP53 | |
| SCHEMBL15116495 | 0.75 | CYP3A4 (0.43) | TRPA1AAK1LMNAMAPTHPGD | |
| SCHEMBL28586691 | 0.75 | AAK1 (0.46) | TRPA1AAK1LMNASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7161002-B2 | Syntheses of quinazolinones | CYTOKINETICS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7009049-B2 | Syntheses of quinazolinones | CYTOKINETICS, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-20060041130-A1 | Syntheses of quinazolinones | CYTOKINETICS, INC. AND SMITHKLINE BEECHAM CORP. | 2006-02-23 | — | — | US | disclosed |
| EP-1480980-A4 | SYNTHESES OF QUINAZOLINONES | CYTOKINETICS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1480980-A2 | SYNTHESES OF QUINAZOLINONES | Cytokinetics, Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040067969-A1 | Syntheses of quinazolinones | CYTOKINETICS, INCORPORATED | 2004-04-08 | — | — | US | disclosed |
| WO-2003070701-A2 | SYNTHESES OF QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067969-A1 | Syntheses of quinazolinones | NDUFS3, NDUFS2, NQO2 | TRPA1 2328/4885TNKS 237/4885PARP1 410/4885 |
| US-20060041130-A1 | Syntheses of quinazolinones | NDUFS3, NDUFS2, NQO2 | TRPA1 2328/4885TNKS 237/4885PARP1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.